학술논문
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
Document Type
article
Author
Christian M Lange; Stephanie Bibert; Zoltan Kutalik; Philippe Burgisser; Andreas Cerny; Jean-Francois Dufour; Andreas Geier; Tilman J Gerlach; Markus H Heim; Raffaele Malinverni; Francesco Negro; Stephan Regenass; Klaus Badenhoop; Jörg Bojunga; Christoph Sarrazin; Stefan Zeuzem; Tobias Müller; Thomas Berg; Pierre-Yves Bochud; Darius Moradpour; Swiss Hepatitis C Cohort Study Group
Source
PLoS ONE, Vol 7, Iss 7, p e40159 (2012)
Subject
Language
English
ISSN
1932-6203
Abstract
BACKGROUND:To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C. METHODOLOGY/PRINCIPAL FINDINGS:Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D(3) (25[OH]D(3)) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061-2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D(3)